Feb 26 (Reuters) - FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement. (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | +1.96% | -9.57% | +17.34% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
11,988 GBX | -0.32% | +9.52% | 231B | ||
1.04 USD | +1.96% | -9.57% | 103M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.34% | 103M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FGEN Stock
- News FibroGen, Inc.
- FibroGen regains rights to anemia drug from AstraZeneca